Inogen (INGN)
(Delayed Data from NSDQ)
$9.62 USD
-0.08 (-0.82%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $9.62 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.62 USD
-0.08 (-0.82%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $9.62 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Zacks News
Inogen (INGN) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.
Why Is Shockwave Medical (SWAV) Down 8.3% Since Last Earnings Report?
by Zacks Equity Research
Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) third-quarter results benefit from higher revenues in its domestic business-to-business sales channel.
Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 56.10% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Inogen (INGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shockwave Medical (SWAV) Up 6.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 95% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Inogen (INGN) Stock Now
by Zacks Equity Research
Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.
Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -36.49% and 0.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?